News Related to Retinal Degeneration

Related coverage linked through entity extraction aliases.

Belite Bio Initiates Rolling NDA Submission for Tinlarebant to Treat Stargardt Disease

Jun 13, 2026

Belite Bio has begun a rolling NDA submission for tinlarebant, an oral therapy for Stargardt disease type 1. The drug has Breakthrough Therapy Designation, and the company expects to complete the submission in Q2 2026.

Ray Therapeutics Receives EMA PRIME Designation for RTx-015 Gene Therapy in Retinitis Pigmentosa

May 01, 2026

Ray Therapeutics received EMA PRIME designation for its RTx-015 optogenetic gene therapy for retinitis pigmentosa, following recent FDA RMAT status. The company also appointed Michael Murtagh as Chief Regulatory Officer to support global development.